CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-28 | Patel Naimish Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2024-05-28 | Patel Naimish Chief Medical Officer | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2024-05-23 | Bruno Julianne Chief Operating Officer | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2024-04-15 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +19,582 | $19.12 | $374K | 227,704 |
| 2024-04-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −18,378 | $59.88 | $1.1M | 209,326 |
| 2024-04-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −1,204 | $60.40 | $73K | 208,122 |
| 2024-04-15 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,582 | 0 | ||
| 2024-03-20 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +33,333 | 33,333 | ||
| 2024-03-20 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Restricted Stock Units | +25,000 | 25,000 | ||
| 2024-03-20 | Prasad Raju Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +36,168 | 36,168 | ||
| 2024-03-20 | Prasad Raju Chief Financial Officer | Grant or award · Restricted Stock Units | +25,000 | 25,000 | ||
| 2024-03-20 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2024-03-20 | Kulkarni Samarth Chief Executive Officer | Grant or award · Restricted Stock Units | +78,750 | 78,750 | ||
| 2024-03-15 | Prasad Raju Chief Financial Officer | Sale | −3,524 | $72.69 | $256K | 6,476 |
| 2024-03-15 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +20,000 | $19.12 | $382K | 228,122 |
| 2024-03-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −10,613 | $71.97 | $764K | 217,509 |
| 2024-03-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −9,387 | $73.06 | $686K | 208,122 |
| 2024-03-15 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 19,582 | ||
| 2024-03-14 | Prasad Raju Chief Financial Officer | Option exercise | +10,000 | 10,000 | ||
| 2024-03-14 | Prasad Raju Chief Financial Officer | Option exercise · Restricted Stock Units | −10,000 | 30,000 |
Page 13 of 46 · 910 trades